ClinicalTrials.gg
Active, not recruitingNCT06974266AKM Lab-01Updated Oct 9, 2026

An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia

An interventional study of Probiotic and Placebo in Hypercholesterolaemia, sponsored by Moon (Guangzhou) Biotechnology Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Moon (Guangzhou) Biotechnology Co., Ltd. · Not applicable, Interventional, and Treatment

Updated Oct 9, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Planned enrollment
39th of 53
60 · median 207
Started
2025
with 3 others
No phase
7 of 59
3 open now
Primary completion
2026-10
later than 6 of 16 live
Registered
53rd of 59
by date

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 39th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 53rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to assess the safety and efficacy of AKM Lab-01 in subjects with hypercholesterolemia. This study will be conducted as a randomized, double-blind, placebo-controlled trial, eligible hypercholesterolemic participants were administered daily oral doses of either AKM Lab-01 or a placebo. Baseline clinical parameters, blood samples, and stool specimens were collected before and after the intervention for comparative analysis.

03

Conditions studied

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 35-75 years (inclusive), regardless of gender;
  2. Patients diagnosed with hypercholesterolemia (5.2 mmol/L ≤ TC \<6.2 mmol/L, or 3.4 mmol/L ≤ LDL-C \<5.0 mmol/L), with or without hypertriglyceridemia (1.7 mmol/L ≤ TG \<4.5 mmol/L) or mixed hyperlipidemia (defined as: 1.7 mmol/L ≤ TG \<4.5 mmol/L and 5.2 mmol/L ≤ TC \<6.2 mmol/L; or 1.7 mmol/L ≤ TG \<4.5 mmol/L and 3.4 mmol/L ≤ LDL-C \<5.0 mmol/L; or 1.7 mmol/L ≤ TG \<4.5 mmol/L, 5.2 mmol/L ≤ TC \<6.2 mmol/L and 3.4 mmol/L ≤ LDL-C \<5.0 mmol/L);
  3. Accompanied by overweight/obesity (24.0 ≤ ≤40.0 kg/m²);
  4. Have not taken any metabolic control medications (for lipid, weight, or blood glucose) within the past month;
  5. Have controlled of blood lipids solely through lifestyle interventions (diet and exercise) for at least 1 month prior to the screening period;
  6. People must possess communication and cognitive abilities to adhere to long-term medication, and fully understand the nature, significance, potential benefits, inconveniences, and risks of the study before participation;
  7. Fertile patients (male or female) must agree to use at least one medically approved method (e.g., intrauterine device [IUD], oral contraceptives, or condoms) during the trial. Female with must have a negative blood pregnancy test during screening and must not be lactating;
  8. Voluntary enrollment with signed , and commitment to comply with the trial treatment regimen and visit schedule

Exclusion criteria

Exclusion Criteria:

  1. Have taken any metabolic control medications (e.g., lipid-lowering, blood glucose-regulating, or weight-loss drugs) within the past month or are currently taking such medications.
  2. Patients with secondary hyperlipidemia caused by conditions such as nephrotic syndrome, liver diseases, hypothyroidism, renal failure, etc..
  3. Have severe comorbidities requiring immediate treatment, including uncontrolled diabetes, hypertriglyceridemia, cerebrovascular diseases, etc., as determined by the investigator.
  4. Have severe primary diseases (e.g., hepatic, renal, or hematopoietic system disorders) or psychiatric conditions.
  5. Patients with a family history of genetically inherited metabolic disorders.
  6. Currently taking liver-affecting medications.
  7. Have a history of bariatric surgery.
  8. People with acute or chronic progressive/unstable diseases deemed unsuitable for enrollment by the investigator.
  9. Hepatic or renal dysfunction: (ALT) or aspartate aminotransferase (AST) >2.5× (ULN); Total >1.5×ULN; Serum creatinine (Cr) >1.5×ULN.
  10. Serum amylase ≥1.5×ULN or other laboratory abnormalities per investigator judgment.
  11. Patients with acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) within the past 3 months.
  12. Have a history of gastrointestinal surgery within the past year.
  13. People with allergic constitution or to the product.
  14. Have used antibiotics, probiotics, or prebiotics within 3 months prior to recruitment.
  15. Excessive alcohol consumption in the past decade (>30 g/day for males; >20 g/day for females).
  16. Pregnant or breastfeeding subjects.
  17. Excluded for other reasons as determined by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Probiotic

    Subjects receive AKM Lab-01 Enteric-coated Capsule

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Subjects receive placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Subjects receive AKM Lab-01 Enteric-coated once daily by oral, 34B TFU/day , within half an hour after breakfast for 3 months.

  • Dietary supplementPlacebo

    Subjects receive placebo once daily by oral, one capsule/day, within half an hour after breakfast for 3 months.

06

What researchers measure

Primary outcomes

  1. Changes in TC and LDL-C

    The changes in serum TC and LDL-C of participants from baseline

    Time frame: Baseline, Day30,Day90

  2. AE and SAE

    During the trial, all subjects are observed and recorded for any adverse events (AEs) that occur during the study period, the incidence, type and severity of serious adverse events (SAEs), including clinical symptoms and abnormalities in vital signs, and abnormalities in lab tests, with determination of the correlation between them and the investigational drug.

    Time frame: Up to 4months

Secondary outcomes

  1. Changes in Blood Lipids

    Changes of participants from baseline in HDL-C and Triglyceride

    Time frame: Baseline, Day30, Day90

  2. Changes in FBG

    Changes of participants from baseline in Fasting blood glucose (FBG)

    Time frame: Baseline, Day30, Day90

  3. Changes in Blood Pressure

    Changes of participants from baseline in blood pressure

    Time frame: Baseline, Day30, Day90

  4. Changes in Uric Acid

    Changes of participants from baseline in Uric Acid

    Time frame: Baseline, Day30, Day90

  5. Changes in Weight

    Changes of participants from baseline in weight

    Time frame: Baseline, Day30, Day90

  6. Changes in HbA1c

    Changes of participants from baseline in HbA1c

    Time frame: Baseline, Day30, Day90

  7. Changes in Waist Circumference and Hip Circumference

    Changes of participants from baseline in waist circumference and hip circumference

    Time frame: Baseline, Day30, Day90

  8. Changes in Body Fat Percentage

    Changes of participants from baseline in body fat percentage

    Time frame: Baseline, Day30, Day90

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 151 interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 16 months is close to that.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 15, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Oct 30, 2026was Jul 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 9, 2026
Primary completion
Jul 30, 2026→Oct 30, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 30, 2026→Oct 30, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06974266
Lead sponsor
Moon (Guangzhou) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jun 25, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion